Page 9 - Srne News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Not content with boasting a pipeline bursting at the seams with multiple candidates in various stages of development, Sorrento Therapeutics (SRNE) has now added another arrow to the quiver. On Monday, the company announced it is forming a new subsidiary called ADNAB. The new entity will advance and commercialize a technology platform which was developed by the Mayo Clinic to produce antibody-drug conjugates (ADC). The platform has been exclusively licensed to Sorrento. An immune complex of nanoparticle albumin-bound drug products, which are non-covalently connected to tumor-targeting monoclonal antibodies (mAb’s), ADNAB was developed by Svetomir Markovic, M.D., Ph.D., and his team of researchers at Mayo Clinic. Nine potential ADNAB candidates have been created by the team, two of which are currently in the process of enrolling patients for an FDA-supervised, human trial. The ADNAB platform will make use of Sorrento’s G-MAB library of fully humanized monoclonal antibodies,

Tiprank best stocksMayo clinicTechnology platformStages of developmentMonoclonal antibodiesProduct candidatesமயோ சிகிச்சையகம்தொழில்நுட்பம் நடைமேடைநிலைகள் ஆஃப் வளர்ச்சிப்ராடக்ட் வேட்பாளர்கள்